The authors, Eric A. Engels and coworkers at the National Cancer Institute, National Institutes of Health, Rockville, MD, the Centers for Disease Control and Prevention, Atlanta, GA, and The Johns Hopkins University School of Medicine, Baltimore, MD, studied 254 zoo workers, 109 of whom handled primates extensively and the remainder not at all. An antibody assay showed that SV40 reactivity was more common among primate workers (23 percent) than among the other workers (10 percent). These low rates, which suggested absence of ongoing SV40 replication, contrasted with assay results showing 85 percent and 56 percent reactivity, respectively, for two other polyomaviruses, BK and JC, which are highly prevalent in humans and establish lifelong infection.
When the investigators used particles of SV40, BK, and JC to evaluate whether SV40-positive reactions were specific or represented cross-reacting antibody responses, only 14 of 29 subjects demonstrated specific reactivity. Engels and coworkers commented that this suggested that much of their SV40-positive results were probably due to BK or JC virus cross-reactivity.
The investigators cautioned that there is as yet no definitive evidence that SV40 can persistently infect humans, and that the health consequences of SV40 exposure, including the risk of cancer, are still unknown. Nevertheless, they concluded that their study "suggests that individuals who work closely with nonhuman primates are occupationally exposed to SV40," and that further studies of the issues involved are needed.
In an accompanying editorial, Keerti Shah of The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, commented that, "although humans in contact with primates may become infected with SV40, currently available evidence does not suggest that SV40 circulates independently in the community or that it contributes to the development of any human cancer." Because of uncertainties in the evidence, however, he recommended further studies, including closer study of those exposed to primates, "that investigate the 'full signature' of SV40 infection" like genomic sequences, transcripts, antibodies, T cell response, and so on.
Founded in 1904, The Journal of Infectious Diseases (JID) is the premier publication in the Western Hemisphere for original research on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune mechanisms. Articles in JID include research results from microbiology, immunology, epidemiology, and related disciplines. It is published under the auspices of the Infectious Diseases Society of America (IDSA), a professional society based in Alexandria, Va., representing nearly 8,000 physicians and scientists who specialize in infectious diseases. (For more information, visit www.idsociety.org.) Nested within the IDSA, the HIV Medicine Association (HIVMA) is the professional home for more than 2,600 physicians, scientists and other health care professionals dedicated to the field of HIV/AIDS. HIVMA promotes quality in HIV care and advocates policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice. (For more information, visit www.hivma.org.)